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SH-SY5YNeuroblastoma is a childhood cancerwith high incidence and highmortality rate. Great efforts aremade toﬁndnew
treatments and molecular markers for diagnosis and prognosis. miRNAs stand for novel strategies to modulate
tumor growth, as they can act either as tumor suppressors or as oncogenes. Morphine is an opioid agonist widely
used to treat severe and chronic pain, as for example cancer pain. Previous studies have revealed that morphine is
able to modify cancer progression, by acting on proliferation or on apoptosis; however, up to date, the available re-
sults are contradictory, maybe due to the different doses used, routes of administration and model systems. While
some studies show that morphine promotes cell proliferation and metastasis, other authors sustain that morphine
effect is mainly antiproliferative and pro-apoptotic. In this study we aim to establish the effect of chronic opiate ad-
ministration on cell proliferation in the neuroblastoma SH-SY5Y cell line. Lowdoses ofmorphine (10 nM)promoted
cell proliferation in undifferentiated cells and reduced the expression levels ofmiR133b, while higher doses (1 μM)
inhibited cell proliferation and correlated with decreased levels ofmiR133b andmiR128without triggering apopto-
sis. Naloxone, the classical opioid antagonist, could not fully block the effect of morphine onmiR128 expression, so
that the observed effectmaybemediated bynon-opioidmechanisms. Our results represent a further contribution to
the hypothesis that a joint regulation ofmiRNA networks and the speciﬁc characteristics of the target tissuemay de-
termine the effect of morphine on tumor cell growth.
© 2014 Published by Elsevier B.V.1. Introduction
Neuroblastoma is a tumor that appears in childhood with high inci-
dence and mortality rate. This tumor of the nervous system occurs dur-
ing the embryonic stage or at the early postnatal age, and impairs the
growth of sympathetic cells derived from the neural crest. It is the
most common malignant tumor in infants, besides being responsible
for a dramatic percentage of pediatric cancer [1]. Thus, great efforts
are made to ﬁnd new treatment strategies and molecular markers for
diagnosis and prognosis. miRNA targeting stands for a novel approach
to modulate tumor growth, as it can be the case of neuroblastoma [1,2].NF, brain derived neurotrophic
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vier B.V.miRNAs are small non-coding single-stranded RNAs of approximate-
ly 22 bp, that act as regulators of gene expression at the post-
transcriptional level. It has been estimated that about 30% of all human
genes are regulated by miRNAs by binding to their 3′UTR [3]. It is
known that miRNAs are involved in the control of neural development
by modulating cell proliferation, differentiation, adult neurogenesis and
apoptosis [4,5]. Besides, miRNAs can control some neuronal functions
like plasticity [5] and miRNA homeostasis is linked to some pathological
states [6], as for example neurological disorders like Parkinson disease
[5,7]. miRNAs are also deregulated in many tumors, and they can act ei-
ther as tumor suppressors or oncogenes, depending on their targets [5].
ThereforemiRNAs and other non-coding RNAs arise as novel therapeutic
strategies in cancer research [8]. In fact, it has been already proven that
mice with neuroblastoma show differences in pro-apoptotic and anti-
angiogenic activities when treated with nanoparticles encapsulating
miR-34a, which speciﬁcally targets this type of tumor [9].
miR133b is speciﬁcally expressed in a subpopulation of dopaminergic
cells located in themidbrain, and regulates their differentiation, matura-
tion and neuronal function [7,10]. This miRNA is also deregulated in sev-
eral types of cancer, as for example colorectal [11,12] and bladder cancer
[13]. It has also been reported thatmiR133b targets twoprosurvivalmol-
eculeswhich aremembers of theBCL-2 (B-cell CLL/lymphoma212) fam-
ily in adenocarcinoma cell lines [14].
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(miRNA128-1 and miR128-2) which give rise to two identical miRNAs
in their mature form [15]. Studies performed in the neuroblastoma SH-
SY5Y cell line indicate thatmiR128 represses the expression of the trun-
cated isoform of the human neurotrophin-3 receptor gene (NTRK3),
andmodulates the expression of genes involved in cytoskeletal reorgani-
zation, apoptosis, cell survival and proliferation. Overexpression of
miR128 up-regulates the anti-apoptotic gene BCL-2 [16]. Another study
performed in the same cell line revealed thatmiR128 targets and down-
regulates the expression of reelin and doublecortin (DCX), two genes
which are related to neuroblastic migration; thereforemiR128 decreases
neuroblastoma growth and cell motility, thus affecting invasiveness [15].
Morphine is an opioid agonist widely used to treat severe and chronic
pain, as for example cancer pain. It has been shown that, apart from its an-
algesic properties, morphine elicits other side effects. Previous studies
have revealed that morphine is able to modify cancer progression, either
by acting on proliferation or on apoptosis [17]. However, up to date, the
published results are contradictory [18], and some authors raise the ques-
tion whether the μ opioid receptormight not play a signiﬁcant role in the
regulation opioid-mediated tumor growth [17]. Several studies indicate
that the opioid growth factor receptor (OGFR) can be involved in the
modulation of tumor progression elicited bymorphine [19]. In vivo exper-
iments revealed that the duration of the opioid receptor blockade by nal-
trexone modulates neuroblastoma progression [20]. Some other studies
pointed out thatmorphine can promote tumor growth due to its inhibito-
ry effect on the immune response [21]. Other authors have shown that
that the μ opioid receptor expression is increased in several non-small
cell lung cancer cell lines as well as in lung tissue from patients with
this type of carcinoma, and that μ opioid receptor activation could be cor-
related with cell growth and metastasis [22].
SH-SY5Y is a human-derived cell line that was developed from the
SK-N-SH cell line, which was obtained from a neuroblastoma. Interest-
ingly, the SH-SY5Y cell line endogenously expresses the μ opioid recep-
tor, which is the pharmacological target for morphine [23]. Exposure to
retinoic acid and/or BDNF (Brain Derived Neurotrophic Factor) can trig-
ger differentiation of SH-SY5Y cells into a homogeneous population of
cellswhich expresses neuronalmarkers and shows a neuron-like pheno-
type [24]. Previous results from our group revealed thatmorphinemight
be regulating cell proliferation in immature neurons by controlling the
expression of miR133b in zebraﬁsh [10]. Given the importance of mor-
phine in the medical practice, and especially in the management of can-
cer pain, in this study we aimed to establish the effect of different doses
ofmorphine on cell proliferation in the neuroblastoma SH-SY5Y cell line.
Besides, we want to determine if the proliferative effect is due to the in-
teraction of morphine with the μ opioid receptor and whether this effect
is mediated by miRNAs, namelymiR133b andmiR128.
2. Materials and methods
2.1. Drugs and chemicals
Morphine hydrochloride was provided by the Spanish Ministry of
Health and naloxone (Nx) was purchased from Sigma-Aldrich. All
other reagents used were from analytical grade.
2.2. Cell culture and drug treatments
The neuroblastoma SH-SY5Y cell line (a kind gift of Dr. D. Martinez-
Zanca) was cultured in DMEM (Dulbecco's modiﬁed Eagle's medium):
HAM F-12 (1:1) supplemented with 10% (v/v) fetal calf serum, 2 mM
glutamine, 100 U mL−1 penicillin and 0.1 mg mL−1 streptomycin (all
from Gibco-BRL, Life Technologies), at 37 °C in humidiﬁed atmosphere
containing 5% (v/v) CO2 in a Forma incubator. Cells were harvested
with 2 mM EDTA in PBS and plated 1 day before the experiment, so
that they reached 70% of conﬂuence on the next day. Cells were divided
into ﬁve experimental groups: 1) control group (freshmediumwithoutdrug), 2) 10 nMmorphine, 3) 1 μMmorphine, 4) 10 μM naloxone and
5) 10 μM naloxone + 1 μM morphine (cells were preincubated with
10 μM naloxone for 1 h prior to the treatment with 1 μM morphine).
Cells were further cultured for 24 h and then processed as needed.
2.3. Retinoic acid-induced differentiation of SH-SY5Y neuroblastoma cell
line
To induce the cellular differentiation by retinoic acid in vitro, we
have followed the procedure described in [24]. Brieﬂy, cells were seed-
ed at 65% conﬂuency 1 day in advance and cultured in DMEMwith 15%
(v/v) fetal calf serum. Cells were exposed to 10 μM retinoic acid in 0.1%
ethanol for 8 days and medium was changed every other day. After
8 days, cells were detached from the ﬂask and exposed to different
drug treatments as established before.
2.4. Immunocytochemical studies
Cells were grown on poly-lysinated coverslips which were put on
12-well plates (2 coverslips per well) and exposed to drug treatments
as previously described. After 24 h incubation, cells were ﬁxed with
4% paraformaldehyde and washed with PBST. For proliferation assays,
themouse anti-histone3 (phospho Ser10) (Abcam)was used as primary
antibody and Alexa Fluor 488 conjugated anti-mouse (Molecular
Probes, Life Techonologies) as secondary antibody. Negative controls
(no primary or secondary antibody) were performed in parallel.
TUNEL assays to determine apoptosis were performed using the In
Situ Cell Death Detection Kit, AP (Roche Applied Science) following
the manufacturer's instructions. Positive (cells treated with DNase I)
and negative (no TDT enzyme) controls were performed in parallel.
Cell nuclei were counterstained with 4,6-diamidino-2-phenylindole
(DAPI) (Roche Applied Science). Experiments were performed in dupli-
cates and repeated three times.
Samples were analyzed with an Olympus AX70 ﬂuorescence micro-
scope. Five images were taken from each treatment and for each experi-
mental series. Image analysis and cell counting were performed with
ImageJ software (NIH). The percentage of cells in proliferation or in apo-
ptosis was normalized to the total number of cells and data were repre-
sented and analyzed by using GraphPad Prism software (San Diego, CA,
USA).
2.5. Quantitative real-time PCR analysis
Cells were exposed to the different drug treatments, then harvested
and the cell pellet was stored at−80 °C until use. Total RNA from cells
was isolated by using the Trizol reagent (Invitrogen, Life Technologies)
and treated with DNase I (Roche Applied science). For GAPDH and
OPRM1 genes, 1 μg RNA was reversed transcribed by using the M-
MuLV retrotranscriptase (New England Biolabs) and random hexamers.
To perform the real-time PCR on miRNAs (bothmiR133b and miR128),
cDNAwas synthesized following the procedure described in [25]. Brief-
ly, prior to the cDNA synthesis, total RNAwaspolyadenylatedwith poly-
A polymerase (New England Biolabs) and then reverse transcribedwith
theM-MuLV retrotranscriptase (New England Biolabs). The sequence of
the qPCR primers is given in Table 1. The ampliﬁcation reactions were
carried out in a ﬁnal volume of 25 μL by using Power SYBR Green PCR
Master Mix (Applied Biosystems, Life Techonologies) and the real-
time polymerase chain reaction was performed by using the ABI Prism
7300 (Applied Biosystems). Experiments were conducted in triplicates
and repeated four times. Ct values were calculated with the SDS v1.3.1
software (Applied Biosystems, Life Technologies) for each gene and
the cDNA abundance of each transcriptwas calculated relative to the ex-
pression of the housekeeping geneGAPDHusing the REST-384© v2 soft-
ware [26]. Also, standard curves for each gene and negative controls
were included in each PCR reaction. Statistical analysis was performed
by using GraphPad Prism software (San Diego, CA, USA).
Table 1
Primers used for qPCR analysis. Summary of the primers that have been used in qPCR
experiments, ENSEMBL gene ID and amplicon length.
Gene ENSEMBL
gene ID
qPCR primer sequence Amplicon
length
miR133b ENSG00000199080 F: 5′ GTTTGGTCCCCTTCAAC 3′
R: 5′ AGTTTTTTTTTTTTTTTAGCTG
GTT 3′
39 nt
miR128 ENSG00000207654 F: 5′ CACAGTGAACCGGTCT 3′
R: 5′ GTCCAGTTTTTTTTTTTTTTTAAA
GAG 3′
41 nt
oprm1 ENSG00000112038 F: 5′ CGGAAACTTCCTGGTCATGT 3′
R: 5′ CTGCCAGAGCAAGGTTGAA 3′
89 nt
gapdh ENSG00000111640 F: 5′ CTGACTTCAACAGCGACACC 3′
R: 5′ CCCTGTTGCTGTAGCCAAAT 3′
120 nt
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3.1. Changes in proliferation in the SH-SY5Y neuroblastoma cell line elicited
by morphine
To determine if morphine can alter proliferation in a neuroblastoma
model, the SH-SY5Y cell line was incubatedwith different doses ofmor-
phine, 10 nM (a subeffective dose) and 1 μM (an analgesic dose). ToFig. 1.Morphine disrupts proliferation in the neuroblastoma SH-SY5Y cell line. Cells were treated w
Phospho-histone 3 (Ser10) immunostaining (green) has been used to labelmitotic cells and the
an increase in cell proliferation,whereas the 1 μMdose reduced the number of phospho-histone
(alone or in co-incubation with morphine).establish if the proliferative effect is mediated by the m opioid receptor,
the universal antagonist naloxonewas also used at 10 mM, alone and in
combination with 1 mM morphine. An antibody against the mitotic
marker phospho-histone 3 (Ser10) was used to label the proliferative
cells, images were acquired, mitotic and total nuclei were counted and
the percentage of cells in proliferation was calculated. As seen in
Figs. 1 and 4a, there was a statistically signiﬁcant increase of phospho-
histone 3 positive nuclei in the group of cells incubated with the lower
dose of morphine (10 nM), and a decrease in those cells exposed to
the higher dose (1 μM). No changes were seen when the cells were in-
cubatedwith naloxone, either alone or in co-incubationwithmorphine.
In order to assess if morphine could also be affecting apoptosis and
thus explaining the changes in cell proliferation, TUNEL assays were
performed (Fig. 2). Quantiﬁcation analysis revealed that there were no
statistically signiﬁcant changes in the percentage of apoptotic nuclei
for any of the tested doses of morphine and naloxone (Fig. 4b).
3.2. Morphine does not alter proliferation in differentiated SH-SY5Y cells
The SH-SY5Y cell linewas culturedwith retinoic acid to promote cell
differentiation into a neuronal phenotype; then cells were treated with
morphine and naloxone as previously described. Proliferation studies
were conducted and quantiﬁcation of cell proliferation was performedith different concentrations of morphine and/or naloxone, and proliferation was assayed.
cell nuclei have been counterstainedwith DAPI (blue). Note that 10 nMmorphine induced
3 positive nuclei, as compared to untreated cells, and cells incubatedwith 10 μMnaloxone
Fig. 2. Apoptosis assays on the neuroblastoma SH-SY5Y cell line after opiate treatment. To determine if opiate treatment promotes apoptosis, cells were exposed to different concentrations of
morphine and/or naloxone, and programmed cell deathwas determined by TUNEL staining. Apoptotic nuclei were labeled in green and total nuclei were counterstainedwith DAPI (blue).
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alter the fraction of nuclei labeled with phospho-histone 3 antibody
after retinoic acid treatment; naloxone had no affect on cell prolifera-
tion, neither alone nor in co-incubation with morphine.
3.3. miR133b and miR128 are differentially regulated by morphine in
SH-SY5Y cells
We next questioned if treatment with different doses of morphine
could alter the expression levels of miR133b and miR128 in the SH-
SY5Y cell line. Real-time PCR analysis allowed us to quantify the expres-
sion levels of these twomiRNAs, and results are summarized in Table 2.
miR133b followed a dose–response curve, as 10 nMmorphine reduced
about 30% ofmiR133b expression, but its levels dropped downup to 65%
when the 1 μM dose was used. No statistically signiﬁcant changes wereobserved when cells were incubated with naloxone, either alone or in
co-incubation with morphine. In the case ofmiR128, the effect of mor-
phine showed a biphasic model, as the 10 nM dose increased miR128
levels (20% increase, but not statistically signiﬁcant), but they were sig-
niﬁcantly reducedwhen cellswere incubatedwith 1 μMmorphine (65%
reduction). No changes in miR128 expression were seen after 10 μM
naloxone treatment. Interestingly this opioid antagonist was not able
to fully reverse the effect of morphine, as the co-incubation with
10 μM naloxone and 1 μMmorphine reduced the expression levels of
miR128 about 38%. On a further step, wewanted to rule out that the dif-
ferential effect ofmorphine could be due to changes in the expression of
the μ opioid receptor after drug treatment. To prove this, real-time PCR
assays were performed, and no signiﬁcant changes in the expression
levels of OPRM1 (the human opioid receptor mu gene) were seen after
any of the drug treatments used in this study.
Fig. 3. Proliferation of retinoic acid-differentiated SH-SY5Y cells after opiate treatment. Cells were culturedwith retinoic acid to promote differentiation into neuron phenotype and thenwere
treated with 10 nM, 1 μMmorphine, 10 μMnaloxone and 1 μMmorphine + 10 μM naloxone. Phospho-histone 3 (Ser10) immunostaining (green) labels mitotic cells and the cell nuclei
have been counterstained with DAPI (blue).
Fig. 4.Quantiﬁcation analysis of a) SH-SY5Y cells in proliferation and b) apoptotic cells after opioid treatment and c) retinoic acid-differentiated SH-SY5Y cells. Data represent themean ± S.E.M.
of the percentage of undifferentiated SH-SY5Y cells in a) proliferation (phospho-histone 3 positive) and b) in apoptosis (TUNEL positive) of the total number of cells (cell nuclei counter-
stained with DAPI) in untreated controls and after treatment with different doses of morphine and naloxone. c) Fraction of retinoic acid-differentiated SH-SY5Y cells undergoing mitosis
after opiate treatment. Data obtained from the drug treatmentswere compared to data from untreated controls and resultswere analyzed by unpaired t test withWelch's correction using
Graph Pad Prism software. * — p b 0.05; ** — p b 0.01; *** — p b0.001.
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Table 2
Quantitative gene expression analysis of miR133b,miR128 and OPRM1measured by real-time PCR in the neuroblastoma SH-SY5Y cell line after opiate treatments. Results represent the relative
gene expression fold-changes formiR133b,miR128 and OPRM1 in SH-SY5Y cells that were exposed to different doses of morphine and/or naloxone. Data shown are normalized to GAPDH.
Results were analyzed by one-way ANOVA followed by Tukey's post-hoc test; asterisks indicate statistical signiﬁcance (*— p b 0.05 and *** — p b 0.001).
Morphine 10 nM Morphine 1 μM Naloxone 10 μM Naloxone 10 μM + morphine 1 μM
miR133b 0.70 ± 0.07 (*) 0.36 ± 0.07 (***) 0.76 ± 0.09 0.95 ± 0.06
miR128 1.21 ± 0.08 0.37 ± 0.04 (***) 0.96 ± 0.09 0.62 ± 0.05 (***)
OPRM1 1.12 ± 0.19 1.34 ± 0.27 1.33 ± 0.26 1.30 ± 0.30
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It is well known that morphine administration can alter tumor
growth; however the evidence obtained up to now is rather conﬂicting,
maybe due to the different doses used, routes of administration and
model systems (i.e.in vivo or in vitro models). Even more, it has been
proposed that some of the proliferative effects triggered by morphine
could be caused by non-opioid mechanisms [18]. In this study we
have used a cell line derived from a neuroblastoma and which endoge-
nously expresses the μ opioid receptor. We have analyzed the effect of
two different doses of morphine, 10 nM (a subpharmacological dose)
and 1 μM (an analgesic dose) and whether the outcome can be blocked
by the universal opiate antagonist naloxone when used at higher con-
centrations than morphine.
Our results indicate that low doses of morphine (10 nM) promote
cell proliferation and reduce the expression levels of miR133b
(Table 3). On its turn, analgesic doses of morphine (1 μM) inhibit prolif-
eration, which is signiﬁcantly correlated with decreased levels of both
miRNAs,miR133b andmiR128. These effects were only seen in undiffer-
entiated cells, as no changes in the proliferation rate were found for
retinoic acid-differentiated SH-SY5Y. None of the treatments altered
the expression levels of OPRM1, so that changes in the transcriptional
activity of the μ opioid receptor gene cannot be responsible for the pro-
liferative effects of opiate agents. Besides, none of the drug treatments
used in this study caused any changes in the apoptosis rate, thus ruling
out the possibility that 1 μMmorphinewas triggering programmed cell
death rather that blocking proliferation.
Interestingly, coincubation of morphine and naloxone (the classical
opioid antagonist) causes a decrease in miR128 levels. Therefore, while
the effect of morphine on proliferation and on the expression of
miR133b is blocked by naloxone, this opioid antagonist is not able to
fully reverse the effect of morphine on miR128 expression. It is hence
probable that this effect is not due to a classical opioid interaction that
can be blocked by the universal antagonist. In this line of thinking, it
has been previously shown that non-opioid actions of opioid peptides
can be elicited via the opioid growth factor receptor (OGFR), which
has antiproliferative effects [27]. In fact, theOGFR is expressed in several
types of cancer, such as pancreatic and thyroid cancer [28,29], and over-
expression of OGFR promotes inhibition of cell growth via a μ-receptor
independent mechanism.
It is well known that the opioid receptors are able to activate the
MAPK signaling pathway after agonist binding; this intracellular cas-
cade controls cell proliferation, differentiation and apoptosis [30]. It
has been shown that μ and δ agonists stimulate the proliferation ofTable 3
Summary table of the effect of opioid agents in the neuroblastoma SH-SY5Y cell line. Results are repr
asterisks indicate statistical signiﬁcance (* — p b 0.05 and *** — p b 0.001).
10 nMmorphine 1 μMm
Proliferation in undifferentiated SH-SY5Y 231% (*) 28.38%
Apoptosis 101% 105%
Proliferation in RA-differentiated SH-SY5Y 101.5% 91%
miR133b levels 70% (*) 36% (**
miR128 levels 121% 37% (**
oprm1 mRNA levels 112% 134%neural progenitors in the adult hippocampus via ERK1/2 [31]. Our pro-
liferation results are in accordancewith previous studies, which showed
that lower doses ofmorphinepromoted tumor growth, but higher doses
were able to inhibit metastasis [22]. Besides, it is well known that
miRNAs can be modulating proliferation and that they are deregulated
in some cancers. Here we show that the opposing effects of morphine
on tumor growth could be due to differential modulation of miRNAs,
in our case miR133b and miR128. Decreased levels of miR133b have
been correlatedwith poor survival andmetastasis in patients with colo-
rectal cancer [11] and prostate cancer [32].miR133b targets pro-survival
genes of the BCL-2 family (MCL-1 and BCL2L2), and its expression levels
are reduced by 28-fold in lung cancer [14]. Ectopic overexpression of
miR133b also inhibits cell growth in prostate cancer by targeting the
epidermal growth factor receptor [33]. On its turn, miR128 regulates
cell survival and proliferation by targeting the truncated NTRK3 recep-
tor in the SH-SY5Y cell line [16]. There is evidence thatmiR128 can act
as anti-oncogenic and pro-differentiation factor. miR128 is repressed
in human glioma tumors and the reduction in the expression levels cor-
relates with malignancy: miR128 targets mitogenic tyrosine kinases
(RTKs), so a down-regulation ofmiR128will release RTKs from its inhib-
itory effect [34]. In humanneuroblastomas,miR128 expression has been
related to better prognosis and less invasiveness properties [15].5. Conclusion
Chronic morphine displays a biphasic effect on cell growth in undif-
ferentiated cells of the neuroblastoma SH-SY5Y cell line: while low
doses of morphine (10 nM) enhance the proliferation rate, higher
doses (1 μM) reduce the number of mitotic cells. The results that we
present here indicate that morphine may be modulating proliferation
through a joint action on miR133b and miR128 in the neuroblastoma
SH-SY5Y cell line. The effects elicited bymorphine cannot be considered
as universalmechanism, but rather a speciﬁc response for each cell type
and tumor process. Our work supports the idea that a joint regulation of
miRNA networks (in our case, miR133b and miR128) and the speciﬁc
characteristics of the target tissuemay determine the effect ofmorphine
on tumor growth.Declarations of interest
All authors declare that this manuscript contains no conﬂict of inter-
est that would prejudice its impartiality.esented as % fold changewhen the tested groups are compared to control group (=100%);
orphine 10 μM naloxone 10 μM naloxone + 1 μMmorphine
(*) 117% 111%
102% 100.6%
97% 94%
*) 76% 95%
*) 96% 62% (***)
133% 130%
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